Cite
HARVARD Citation
Sallman, D. et al. (2019). A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). Leukemia research. pp. 56-61. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Sallman, D. et al. (2019). A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). Leukemia research. pp. 56-61. [Online].